Atlas Trials

Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

Clinical trial NCT04635683 · WITHDRAWN

Trial details

NCT number
NCT04635683
Sponsor
Yazeed Sawalha
Status
WITHDRAWN
Phase
Phase 1
Study type
INTERVENTIONAL
Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueRecurrent Follicular LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3a Follicular LymphomaRecurrent Lymphoplasmacytic LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Nodal Marginal Zone LymphomaRecurrent Splenic Marginal Zone LymphomaRecurrent Waldenstrom Macroglobulinemia
Start date
2022-09-30
Primary completion
2023-12-31
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.